Quantity of eligible clients: CDEC talked about the uncertainty in the amount of sufferers with moderately significant to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some individuals who will be classified as possessing mild or average disease may have a extreme https://aeschylush689wvu9.wikifrontier.com/user